Clinical trials: Relapsing-Remitting
Multiple Sclerosis, Relapsing-Remitting
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
The study is planned to evaluate the cognitive functions in subjects with RRMS treated with interferon beta-1a, and its relationship to the fatigue and neurological dysfunction status.
- Trial name
- SKORE (NCT01075880)
- Testing
- Rebif (Interferon beta-1a)
- Where
- 13 sites in Czechia
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Immunogenicity and Safety Study of Serum-Free Avonex
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.
- Trial name
- NCT00912860
- Testing
- Interferon beta-1a
- Volunteers
- 155 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
- Trial name
- DreaMS (NCT01081782)
- Testing
- ONO-4641
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 407 people
- Sponsor
- Ono Pharma USA Inc
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP
The primary objective is to compare oral dimethyl fumarate (DMF) persistence at six months in relapsing-remitting multiple sclerosis (RR-MS) participants initiating DMF with and without OroSEP patient support program (PSP)…
- Trial name
- TEC-ADHERE (NCT04221191)
- Testing
- Dimethyl Fumarate, PSP
- Where
- 63 sites in France
- Volunteers
- 353 people
- Sponsor
- Biogen
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the efficacy and safety of peginterferon beta-1a produced by CinnaGen compared with CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT05242133
- Testing
- Pegylated interferon beta-1a, Interferon Beta-1A Prefilled Syringe
- Where
- Iran
- Volunteers
- 168 people
- Sponsor
- Cinnagen